KRAS mutations are most frequently found in pancreatic ductal adenocarcinoma (PDAC) (>85%), followed by colorectal cancer (CRC) (~40%), and non-small cell lung cancer (NSCLC) (~30%) [38,39]. This evidence concerns the gene KRAS and colorectal carcinoma.